Motif is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Motif’s pipeline of antibiotics includes iclaprim, which could be ready for commercialization within approximately 36 months, and MTF-001, a preclinical program to design a best-in-class dihydrofolate reductase inhibitor (DHFRi). Discussions and negotiations with academic institutions and pharmaceutical companies are under way to build a portfolio of antibiotic candidates through licensing.
At Motif, members of our team have already developed blockbuster new drugs at the world’s leading pharmaceutical companies and are the named inventors on over 160 U.S.‐issued patents. With our deep drug discovery and development expertise, we have unique proprietary insights to fix flaws of existing first‐in‐class drugs and to design best‐in‐class compounds. We have partnered with leading drug discovery and development companies. Together with a seasoned management team, Motif is positioned to rapidly identify and commercialize novel antibiotics.
Iclaprim is a potential novel antibiotic, designed to be effective against bacteria that have developed resistance to other antibiotics. Iclaprim exhibits potent activity against many genera of staphylococci including MSSA and MRSA.Learn More
MTF-001 is a program to design a best-in-class DHFRi that will be effective against multi-drug resistant bacteria, with the aim of marketing a novel once daily antibiotic that can be administered by injection or taken orally.Learn More
The Antibiotic Crisis
So-called “superbugs” are emerging faster than new, effective antibiotics are being developed. The medical need for new treatments, especially for those with different mechanisms and resistance patterns, is widely recognized.Learn More